Objectives:This study aimed to assess the effects of modified pulmonary rehabilitation(PR)on patients with moderate to severe chronic obstructive pulmonary disease(COPD).Methods:A total of 125 patients(63 in the PR gr...Objectives:This study aimed to assess the effects of modified pulmonary rehabilitation(PR)on patients with moderate to severe chronic obstructive pulmonary disease(COPD).Methods:A total of 125 patients(63 in the PR group and 62 in the control group)were recruited in this study.The patients in the PR group received 12 weeks of conventional treatment,nursing,and modified pulmonary rehabilitation,while the patients in the control group underwent 12 weeks of conventional treatment,nursing,pursed-lip breathing training,and abdominal breathing training.Baseline characteristics,St.George's Respiratory Questionnaire(SGRQ),the six-minute walk test(6MWT),modified medical research council(MMRC)dyspnea scale,and lung function were compared between the two groups.Results:A total of 112 patients(58 patients in the PR group and 54 patients in the control group)completed the 12-week monitoring and follow-up.The SGRQ scores,symptoms(54.933±11.900),activity(52.644±14.334),impact(55.400±9.905),and total score(54.655±10.681)of the PR group did not significantly differ in pre-and post-treatments(P<0.05).No significant change was also observed in the control group(P>0.05).6MWT[(372.089±67.149)m]was significantly improved in the PR group(P<0.05)but was not significantly different in the control group(P>0.05).MMRC(actual rank sum 1719,rank sum 2047.5)was significantly reduced in the PR group(P<0.05)but not in the control group(P>0.05).The lung function(FVC,FEV1,FEV1/FVC,FEV1%and PEF)of the patients in both groups did not significantly change(P>0.05).Conclusion:Modified PR reduces the symptoms of dyspnea,increases exercise capacity,and improves the quality of life of patients with moderate to severe COPD.展开更多
Background: Depression is often viewed as a risk factor for the development of Alzheimer's disease (AD), however little is known regarding the underlying biological mechanisms linking these two diseases. Brain-der...Background: Depression is often viewed as a risk factor for the development of Alzheimer's disease (AD), however little is known regarding the underlying biological mechanisms linking these two diseases. Brain-derived neurotrophic factor (BDNF) has been linked to both cognitive impairment and depression in past research;however few studies have ex-amined this relation in a sample of Alzheimer's patients. The present study sought to address this gap in the literature by examining the relation between serum BDNF levels and depression assessed by the Geriatric Depression Scale (GDS) in a group of patients diagnosed with probable Alzheimer's disease. Methods: Participants included 169 individuals diagnosed with Probable AD enrolled in the TARC Longitudinal Research Cohort with available BDNF levels and GDS scores. The participants were divided into Depressed (N = 20) and Not Depressed (N = 149) based on GDS scores. Re-sults: BDNF levels significantly predicted level (High vs. Low) of depression (β = 0.066, SE = 0.031, p = 0.034). BDNF levels for the Depressed group were significantly higher than those observed in the Not Depressed group (p. > 0.036). Conclusions: These findings suggest that an upregulation of BDNF possibly exists among depressed AD patients as a response to the chronic inflammatory processes that occur in depression. This upregulation of BDNF appears to persist at least into early stages of Alzheimer's.展开更多
目的探究中晚期慢性肾脏病患者失眠严重指数的潜在类别,并分析中晚期慢性肾脏病患者失眠严重指数的预测指标。方法于2023-01~06月采用便利抽样法选取陕西省10所三甲医院的974名中晚期慢性肾脏病患者作为研究对象,采用一般资料调查表和...目的探究中晚期慢性肾脏病患者失眠严重指数的潜在类别,并分析中晚期慢性肾脏病患者失眠严重指数的预测指标。方法于2023-01~06月采用便利抽样法选取陕西省10所三甲医院的974名中晚期慢性肾脏病患者作为研究对象,采用一般资料调查表和失眠严重指数量表(insomnia severity index scale,ISIS)调查中晚期慢性肾脏病患者的失眠严重状况并进行类别分析,探索不同类别间的区分指标。结果中晚期慢性肾脏病患者失眠严重指数特征可分为3种类别,分别命名为中度失眠组、亚临床失眠组、无失眠症状组,占比依次为63.14%、20.43%、16.43%。年龄>50岁(OR=1.547,P<0.001)、无业(OR=1.051,P=0.023)是中度失眠的预测指标;年龄>50岁(OR=1.974,P<0.001)是亚临床失眠的预测指标。结论中晚期慢性肾脏病患者失眠严重指数存在明显不同的分类特征,护理人员应根据患者失眠的不同分类和人口学特征,给予针对性的护理措施与心理护理策略。展开更多
Background： Chronic kidney disease （CKD） with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limit...Background： Chronic kidney disease （CKD） with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limited. This study aimed to assess the efficacy and safety of the traditional Chinese medicine, Niaoduqing particles, for delaying renal dysfunction in patients with stage 3b-4 CKD.Methods： The present study was a prospective, randomized, double-blind, placebo-controlled, naulticentcr clinical trial. Frorn May 2013 to December 2013,300 CKD patients with an estimated glomerular filtration rate （eGFR） between 20 and 45 ml ＂rain ~＂ 1.73 m 2, aged 18-70 years were recruited from 22 hospitals in 11 Chinese provinces. Patients were randomized in a 1：1 ratio to either a test group, which was administered Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks, or a control group, which was administered a placebo using the same methods. The primary endpoints were changes in baseline serum creatinine （Scr） and eGFR after completion of treatment. The primary endpoints were analyzed using Student＇s t-test or Wilcoxon＇s rank-sum test. The present study reported results based on an intention-to-treat （ITT） analysis. Results： A total of 292 participants underwent the ITT analysis. At 24 weeks, the median （interquartile range） change in Scr was 1.1 （-13.0-24.1） and 11.7 （-2.6-42.9） p, mol/L for the test and control groups, respectively （Z = 2.642, P = 0.008）, and the median change in eGFR was -0.2 （-4.3-2.7） and -2.2 （-5.7-0.8） ml.min-1·1.73 m-2, respectively （Z = -2.408, P = 0.016）. There were no significant differences in adverse events between the groups. Conclusions： Niaoduqing particles safely and effectively delayed CKD progression in patients with stage 3b-4 CKD. This traditional Chinese medicine may be a promising alternative medication for patients with moderate-to-severe renal dysfunction.展开更多
基金This work was financially supported by the Instructive Research Program of Changzhou Municipal Commission of Health and Family Planning(WZ201417)
文摘Objectives:This study aimed to assess the effects of modified pulmonary rehabilitation(PR)on patients with moderate to severe chronic obstructive pulmonary disease(COPD).Methods:A total of 125 patients(63 in the PR group and 62 in the control group)were recruited in this study.The patients in the PR group received 12 weeks of conventional treatment,nursing,and modified pulmonary rehabilitation,while the patients in the control group underwent 12 weeks of conventional treatment,nursing,pursed-lip breathing training,and abdominal breathing training.Baseline characteristics,St.George's Respiratory Questionnaire(SGRQ),the six-minute walk test(6MWT),modified medical research council(MMRC)dyspnea scale,and lung function were compared between the two groups.Results:A total of 112 patients(58 patients in the PR group and 54 patients in the control group)completed the 12-week monitoring and follow-up.The SGRQ scores,symptoms(54.933±11.900),activity(52.644±14.334),impact(55.400±9.905),and total score(54.655±10.681)of the PR group did not significantly differ in pre-and post-treatments(P<0.05).No significant change was also observed in the control group(P>0.05).6MWT[(372.089±67.149)m]was significantly improved in the PR group(P<0.05)but was not significantly different in the control group(P>0.05).MMRC(actual rank sum 1719,rank sum 2047.5)was significantly reduced in the PR group(P<0.05)but not in the control group(P>0.05).The lung function(FVC,FEV1,FEV1/FVC,FEV1%and PEF)of the patients in both groups did not significantly change(P>0.05).Conclusion:Modified PR reduces the symptoms of dyspnea,increases exercise capacity,and improves the quality of life of patients with moderate to severe COPD.
文摘Background: Depression is often viewed as a risk factor for the development of Alzheimer's disease (AD), however little is known regarding the underlying biological mechanisms linking these two diseases. Brain-derived neurotrophic factor (BDNF) has been linked to both cognitive impairment and depression in past research;however few studies have ex-amined this relation in a sample of Alzheimer's patients. The present study sought to address this gap in the literature by examining the relation between serum BDNF levels and depression assessed by the Geriatric Depression Scale (GDS) in a group of patients diagnosed with probable Alzheimer's disease. Methods: Participants included 169 individuals diagnosed with Probable AD enrolled in the TARC Longitudinal Research Cohort with available BDNF levels and GDS scores. The participants were divided into Depressed (N = 20) and Not Depressed (N = 149) based on GDS scores. Re-sults: BDNF levels significantly predicted level (High vs. Low) of depression (β = 0.066, SE = 0.031, p = 0.034). BDNF levels for the Depressed group were significantly higher than those observed in the Not Depressed group (p. > 0.036). Conclusions: These findings suggest that an upregulation of BDNF possibly exists among depressed AD patients as a response to the chronic inflammatory processes that occur in depression. This upregulation of BDNF appears to persist at least into early stages of Alzheimer's.
文摘目的探究中晚期慢性肾脏病患者失眠严重指数的潜在类别,并分析中晚期慢性肾脏病患者失眠严重指数的预测指标。方法于2023-01~06月采用便利抽样法选取陕西省10所三甲医院的974名中晚期慢性肾脏病患者作为研究对象,采用一般资料调查表和失眠严重指数量表(insomnia severity index scale,ISIS)调查中晚期慢性肾脏病患者的失眠严重状况并进行类别分析,探索不同类别间的区分指标。结果中晚期慢性肾脏病患者失眠严重指数特征可分为3种类别,分别命名为中度失眠组、亚临床失眠组、无失眠症状组,占比依次为63.14%、20.43%、16.43%。年龄>50岁(OR=1.547,P<0.001)、无业(OR=1.051,P=0.023)是中度失眠的预测指标;年龄>50岁(OR=1.974,P<0.001)是亚临床失眠的预测指标。结论中晚期慢性肾脏病患者失眠严重指数存在明显不同的分类特征,护理人员应根据患者失眠的不同分类和人口学特征,给予针对性的护理措施与心理护理策略。
基金This study was supported by grants from the National Key Technology R＆D Program （Nos. 2013BAI09B05 and 2015BAI12B06）, Key Program of the National Natural Science Foundation of China （No. 81330019）, General Program of the National Natural Science Foundation of China （No. 81270794）, and the Beijing Science and Technology Project （No. D 131100004713003 and No. D171100002817002）.
文摘Background： Chronic kidney disease （CKD） with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limited. This study aimed to assess the efficacy and safety of the traditional Chinese medicine, Niaoduqing particles, for delaying renal dysfunction in patients with stage 3b-4 CKD.Methods： The present study was a prospective, randomized, double-blind, placebo-controlled, naulticentcr clinical trial. Frorn May 2013 to December 2013,300 CKD patients with an estimated glomerular filtration rate （eGFR） between 20 and 45 ml ＂rain ~＂ 1.73 m 2, aged 18-70 years were recruited from 22 hospitals in 11 Chinese provinces. Patients were randomized in a 1：1 ratio to either a test group, which was administered Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks, or a control group, which was administered a placebo using the same methods. The primary endpoints were changes in baseline serum creatinine （Scr） and eGFR after completion of treatment. The primary endpoints were analyzed using Student＇s t-test or Wilcoxon＇s rank-sum test. The present study reported results based on an intention-to-treat （ITT） analysis. Results： A total of 292 participants underwent the ITT analysis. At 24 weeks, the median （interquartile range） change in Scr was 1.1 （-13.0-24.1） and 11.7 （-2.6-42.9） p, mol/L for the test and control groups, respectively （Z = 2.642, P = 0.008）, and the median change in eGFR was -0.2 （-4.3-2.7） and -2.2 （-5.7-0.8） ml.min-1·1.73 m-2, respectively （Z = -2.408, P = 0.016）. There were no significant differences in adverse events between the groups. Conclusions： Niaoduqing particles safely and effectively delayed CKD progression in patients with stage 3b-4 CKD. This traditional Chinese medicine may be a promising alternative medication for patients with moderate-to-severe renal dysfunction.
